by Salynn Boyles, MedPage Today The FDA approved a nebulized formulation of glycopyrrolate (Lonhala Magnair) for long-term maintenance treatment of patients with moderate-to-severe COPD, said manufacturer Sunovion Pharmaceuticals. It's the first long-acting muscarinic antagonist (LAMA) to be sold in this form.
FDA Approves First Nebulized LAMA for COPD
FDA Approves First Nebulized LAMA for COPD
FDA Approves First Nebulized LAMA for COPD
by Salynn Boyles, MedPage Today The FDA approved a nebulized formulation of glycopyrrolate (Lonhala Magnair) for long-term maintenance treatment of patients with moderate-to-severe COPD, said manufacturer Sunovion Pharmaceuticals. It's the first long-acting muscarinic antagonist (LAMA) to be sold in this form.
Comments on this post are for paid subscribers